Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Shares Sold by Abbrea Capital LLC

Abbrea Capital LLC trimmed its stake in shares of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) by 7.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,125 shares of the pharmacy operator’s stock after selling 1,000 shares during the period. Abbrea Capital LLC’s holdings in Walgreens Boots Alliance were worth $343,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Highlander Capital Management LLC acquired a new stake in Walgreens Boots Alliance in the fourth quarter valued at approximately $26,000. Venturi Wealth Management LLC lifted its position in shares of Walgreens Boots Alliance by 1,241.8% in the fourth quarter. Venturi Wealth Management LLC now owns 1,060 shares of the pharmacy operator’s stock valued at $28,000 after acquiring an additional 981 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Walgreens Boots Alliance by 308.4% in the third quarter. EverSource Wealth Advisors LLC now owns 1,119 shares of the pharmacy operator’s stock valued at $25,000 after acquiring an additional 845 shares in the last quarter. Rocky Mountain Advisers LLC purchased a new position in Walgreens Boots Alliance during the fourth quarter worth approximately $30,000. Finally, Planned Solutions Inc. purchased a new position in Walgreens Boots Alliance during the fourth quarter worth approximately $34,000. 58.59% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Inderpal S. Bhandari bought 3,000 shares of the stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average cost of $18.05 per share, with a total value of $54,150.00. Following the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $54,150. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Inderpal S. Bhandari bought 3,000 shares of the stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average cost of $18.05 per share, with a total value of $54,150.00. Following the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $54,150. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Manmohan Mahajan bought 6,000 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were bought at an average cost of $19.38 per share, with a total value of $116,280.00. Following the completion of the purchase, the chief financial officer now directly owns 166,969 shares in the company, valued at $3,235,859.22. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 13,456 shares of company stock valued at $270,423. 17.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on WBA shares. TheStreet upgraded Walgreens Boots Alliance from a “d+” rating to a “c-” rating in a research report on Monday, January 8th. TD Cowen reduced their price objective on Walgreens Boots Alliance from $37.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, April 3rd. Morgan Stanley reduced their target price on Walgreens Boots Alliance from $21.00 to $20.00 and set an “underweight” rating on the stock in a research report on Monday, April 1st. Raymond James restated a “market perform” rating on shares of Walgreens Boots Alliance in a research report on Tuesday, March 26th. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on Walgreens Boots Alliance from $23.00 to $22.00 and set a “hold” rating on the stock in a research report on Wednesday, April 3rd. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $24.36.

Walgreens Boots Alliance Trading Down 1.2 %

Shares of NASDAQ WBA traded down $0.21 during trading on Thursday, reaching $17.60. The stock had a trading volume of 7,842,816 shares, compared to its average volume of 13,908,084. Walgreens Boots Alliance, Inc. has a fifty-two week low of $17.51 and a fifty-two week high of $35.38. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.32 and a current ratio of 0.66. The business’s 50-day moving average price is $20.19 and its 200-day moving average price is $21.84. The company has a market cap of $15.18 billion, a P/E ratio of -2.54, a PEG ratio of 1.12 and a beta of 0.73.

Walgreens Boots Alliance (NASDAQ:WBA) last issued its quarterly earnings data on Thursday, March 28th. The pharmacy operator reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.38. Walgreens Boots Alliance had a positive return on equity of 12.11% and a negative net margin of 4.18%. The business had revenue of $37.05 billion during the quarter, compared to analysts’ expectations of $35.86 billion. During the same period in the previous year, the firm posted $1.16 earnings per share. The company’s revenue was up 6.3% on a year-over-year basis. On average, equities research analysts predict that Walgreens Boots Alliance, Inc. will post 3.23 EPS for the current fiscal year.

About Walgreens Boots Alliance

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.